Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, has completed a successful Series A extension financing round, raising a further €31 million, following the €51 million Series A financing in April 2021. Adcendo’s lead ADC asset, uPARAP, is […]